FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next >>
 
TXT FDA Takes Actions to Curb Autism
09/22/2025
 
 
TXT GDUFA Post-Warning Letter Meeting Guidance
06/18/2025
 
 
TXT Can Surprise Foreign Drug Inspections Boost Safety?
06/10/2025
 
 
TXT FDA Policy Head on Major Trump Changes at FDA
05/19/2025
 
 
TXT Vanda Tradipitant Scheduling Order Out
05/01/2025
 
 
TXT Little Trust in New Health Leaders: Poll
04/30/2025
 
 
TXT Hill Staffer Graham Appointed to FDA Policy Office
04/16/2025
 
 
TXT Celltrion’s Humira Biosimilar Now Interchangeable: FDA
04/16/2025
 
 
TXT Marks’ Firing Challenges RFK Jr.’s Fitness for Office
03/31/2025
 
 
TXT DOGE-Targeted FDA Lab to Remain Open
03/05/2025
 
 
TXT LifeVac Marketing Illegal Airway Device: FDA
10/14/2025
 
 
TXT Astellas’ Pancreatic Cancer Study Misses Endpoint
10/14/2025
 
 
TXT Leukemia Treatment Data Sets Guidance
10/14/2025
 
 
TXT Pfizer’s Tukysa Meets Trial Endpoint
10/14/2025
 
 
TXT FDA Accepts Rocket’s Gene Therapy BLA Resubmission
10/14/2025
 
 
TXT Uzedy Expanded to Include Bipolar I Maintenance
10/14/2025
 
 
TXT Allovate Illegally Marketing Allerdent, FDA Says
10/14/2025
 
 
TXT Medtronic’s Endurant Gains Expanded Indication
10/13/2025
 
 
TXT Troubled Novo Nordisk Facility Gets OAI Status
10/13/2025
 
 
TXT Tvardi’s Lung Disease Drug Falls Short in Trial
10/13/2025
 
 
TXT Regeneron Gene Therapy Improved Rare Hearing Loss
10/13/2025
 
 
TXT Review Extended on Denali’s Hunter Syndrome Drug
10/13/2025
 
 
TXT FDA Approves Celltrion’s Eylea Biosimilar
10/10/2025
 
 
TXT FDA Updates Carvykti Labeling With Boxed Warning
10/10/2025
 
 
TXT GOP Senators Call on FDA to Restrict Generic Mifepristone
10/10/2025
 
 
TXT Glioblastoma Multiforme Drug Gets Orphan Status
10/10/2025
 
 
TXT Prasad Puts Together CBER Leadership Team
10/09/2025
 
 
TXT D.C. Federal Court Backs ‘Carve-Out’ Label
10/09/2025
 
 
TXT Public Rating of FDA, Others Dropping
10/09/2025
 
 
TXT 72% of Breakthrough Drugs Win Approval: Jefferies Analysis
10/09/2025
 
 
TXT Methinks AI Stroke Detection Software Cleared
10/09/2025
 
 
TXT Drug Development Context Inventory Out
10/09/2025
 
 
TXT New Life Medical Selling Unapproved HCT/Ps
10/08/2025
 
 
TXT Create ‘Enhanced Drugs’ Pathway: Petition
10/08/2025
 
 
TXT Complement Therapeutics Gene Therapy Cleared for Trial
10/08/2025
 
 
TXT 3 CGMP Violations at Naturich Cosmetique
10/08/2025
 
 
TXT Trividia Recalls 1 Lot of Glucose Meters
10/08/2025
 
 
TXT FDA Rejects Xspray Pharma’s Leukemia Drug NDA
10/08/2025
 
 
TXT Lilly Partial Win Over FDA’s Biologic Classification
10/08/2025
 
 
TXT AstraZeneca Reports Favorable Hypertension Drug Data
10/07/2025
 
 
TXT Fire CDER, OGD Directors: Members of Congress
10/07/2025
 
 
TXT Statistical Analysis of FDA Warning Letters
10/07/2025
 
 
TXT FDA Warns Technological Medical
10/07/2025
 
 
TXT Multiple Creative Essences Violations
10/07/2025
 
 
TXT FDA Outlines Quicker Path for Lexeo Gene Therapy
10/07/2025
 
 
TXT Former CBER Head Marks Joins Eli Lilly
10/07/2025
 
 
TXT Clinical Hold Lifted on Neurizon ALS Drug
10/06/2025
 
 
TXT Priority Review for Orca Blood Cancer Cell Therapy
10/06/2025
 
 
TXT FDA Authorizes Cryoablation for Low-Risk Breast Cancer
10/06/2025
 
 
TXT 5 Items in Dr. Reddy’s Form FDA-483
10/06/2025
 
 
TXT Abivax Positive Data with Ulcerative Colitis Drug
10/06/2025
 
 
TXT FDA Pilots Speedier Reviews for U.S.-Made Generics
10/03/2025
 
 
TXT Makary Outlines Push to Modernize Drug Reviews
10/03/2025
 
 
TXT 2nd Generic Mifepristone Approved, Prompting Backlash
10/03/2025
 
 
TXT Agency Posts Form-483 for India Vaccine Maker
10/03/2025
 
 
TXT Rocket Pharma Withdraws Gene Therapy BLA
10/03/2025
 
 
TXT Repatha Phase 3 Trial Hits Primary Endpoints
10/02/2025
 
 
TXT Grifols Barcelona Facility Gets FDA-483
10/02/2025
 
 
TXT sBLA for Enhertu in High-Risk Early Breast Cancer
10/02/2025
 
 
TXT FDA Grants Fast Track for Alzheimer’s Drug
10/02/2025
 
 
TXT FDA Touts Sentinel Successes
10/02/2025
 
 
TXT FDA, Vanda Agree on Dispute Actions
10/02/2025
 
 
TXT CDRH Learn Module on Quality Management System
10/01/2025
 
 
TXT 17 New, 64 Revised Product-Specific Guidances
10/01/2025
 
 
TXT FDA Complete Response on Menkes Disease Drug
10/01/2025
 
 
TXT FDA Approves Novartis’ Rhapsido for Urticaria
10/01/2025
 
 
TXT CDRH Proposing 11 Guidances for FY 2026
10/01/2025
 
 
TXT Makary Outlines ‘Mission Critical’ Ops Under Shutdown
10/01/2025
 
 
TXT AbbVie BLA for Treating Rare Blood Cancer
10/01/2025
 
 
TXT WLF Wants End to FDA TV Ad ‘Crackdown’
10/01/2025
 
 
TXT FY 2026 GDUFA Science and Research Priorities
09/30/2025
 
 
TXT No IND Submitted for Study
09/30/2025
 
 
TXT Multiple Violations at Persōn & Covey
09/30/2025
 
 
TXT CDER Head Targets Surrogate Endpoints, Lupus Drug
09/30/2025
 
 
TXT Quantitative Medicine CoE Progress Update
09/30/2025
 
 
TXT Sharp Reductions in FDA Operations Under Shutdown: HHS
09/30/2025
 
 
TXT FDA Approves New Zoll Monitor/Defibrillator
09/30/2025
 
 
TXT OND Custom Medical Queries Are Useful: Article
09/30/2025
 
 
TXT New Guidance on Adaptive Clinical Trial Designs
09/29/2025
 
 
TXT CDRH Expands Recall of BD Alaris Pump Infusion Sets
09/29/2025
 
 
TXT FDA Protected From Firings During Shutdown: Makary
09/29/2025
 
 
TXT Novo Nordisk Resubmits BLA for Once-Weekly Insulin
09/29/2025
 
 
TXT FDA Tells IO Biotech to Delay Cancer Vaccine Filing
09/29/2025
 
 
TXT FDA Expands Device Early Alert Program
09/29/2025
 
 
TXT FDA Presses for Clinical Trial Reporting Compliance
09/26/2025
 
 
TXT AbbVie Files NDA for Parkinson’s Drug Tavapadon
09/26/2025
 
 
TXT Eyeglass Lenses OK'd for Pediatric Nearsightedness
09/26/2025
 
 
TXT FDA Approves New Drug for Acromegaly
09/26/2025
 
 
TXT FDA Rebukes Novartis Over Misleading TV Ad
09/26/2025
 
 
TXT Kennedy, Makary Pledge Mifepristone Review
09/25/2025
 
 
TXT FDA Ends Caprelsa REMS
09/25/2025
 
 
TXT Capricor Gets FDA OK on Duchenne BLA Refiling
09/25/2025
 
 
TXT FDA NextGen Submission Portal Guide
09/25/2025
 
 
TXT Public Confidence in FDA, Others Dropping: Survey
09/25/2025
 
 
TXT Lilly’s Inluriyo OK’d for Breast Cancer
09/25/2025
 
 
TXT CBER Posts 13 FDA Form-483s
09/25/2025
 
 
TXT Biolinq Gets De Novo for Glucose Sensor
09/25/2025
 
 
TXT Cellebration Refusing to Provide Records to FDA
09/24/2025
 
 
TXT Acadia’s Phase 3 Trial of Intranasal Carbetocin Fails
09/24/2025
 
 
TXT Regenerative Therapies Expedited Programs
09/24/2025
 
 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving